I suspect the issue may be, that MSB sees mileage in impressing regulators with multiple PhII trials, across multiple disease types [ie, diabetes and RA]......and aiming for lumping all that data in and saying....."can we get some type of breakthrough/early approval please".
I'm not sure the FDA approves things on the basis of, "They are not just trying one thing; they are trying lots of things, so yeah, in that case we'll give them the green light."
"but I think RA is just about complete with its PhII now and D is done....so a decision point has been arrived at. "
I'm not sure what you mean by "D is done".
Because if it was, a decision would not take so long to make.
It's going on for 10 months since they published Phase2 trial results.
That would be long enough a time period over which to negotiate and conclude a partnership, so they must be close to announcing one, other wise as you said, it would be a pity if they dropped the ball on this one...
- Forums
- ASX - By Stock
- MSB
- Diabetes.......where are we at?
Diabetes.......where are we at?, page-8
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.10 |
Change
-0.025(2.22%) |
Mkt cap ! $1.261B |
Open | High | Low | Value | Volume |
$1.14 | $1.16 | $1.09 | $4.703M | 4.234M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
31 | 338354 | $1.10 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.10 | 56098 | 15 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
31 | 338859 | 1.095 |
39 | 304696 | 1.090 |
13 | 118093 | 1.085 |
19 | 800559 | 1.080 |
6 | 64525 | 1.075 |
Price($) | Vol. | No. |
---|---|---|
1.100 | 55281 | 14 |
1.105 | 117020 | 14 |
1.110 | 163180 | 16 |
1.115 | 220235 | 12 |
1.120 | 167440 | 9 |
Last trade - 13.29pm 29/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |